<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03030235</url>
  </required_header>
  <id_info>
    <org_study_id>D1690C00053</org_study_id>
    <nct_id>NCT03030235</nct_id>
  </id_info>
  <brief_title>Dapagliflozin in Type 2 Diabetes or Pre-diabetes, and PRESERVED Ejection Fraction Heart Failure</brief_title>
  <acronym>PRESERVED-HF</acronym>
  <official_title>Effects of Dapagliflozin on Biomarkers, Symptoms and Functional Status in Patients With Type 2 Diabetes or Pre-diabetes, and PRESERVED Ejection Fraction Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saint Luke's Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Saint Luke's Health System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the impact of dapagliflozin, as compared
      with placebo, on heart failure, disease specific biomarkers, symptoms, health status and
      quality of life in patients with type 2 diabetes or prediabetes and chronic heart failure
      with preserved systolic function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A 12-week randomized, double-blind, placebo-controlled trial to evaluate the effects of
      once-daily dapagliflozin 10 mg on heart failure disease-specific biomarkers (NTproBNP and
      BNP), symptoms, health status, and quality of life in patients with type 2 diabetes or
      prediabetes and chronic heart failure with preserved systolic function. An imaging substudy
      will also be conducted to explore the effects of dapagliflozin vs. placebo on various
      echocardiographic parameters.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in NTproBNP at 6 and 12 weeks</measure>
    <time_frame>Baseline to Week 6 and Week 12</time_frame>
    <description>Change from baseline in NTproBNP at 6 and 12 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in heart failure related quality of life using the Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score over the treatment period</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Change from baseline in heart failure related quality of life using the Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score over the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 6 minute walk test over the treatment period</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Change from baseline in 6 minute walk test over the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in BNP over the treatment period</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Change from baseline in BNP over the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HbA1c over the treatment period</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Change from baseline in HbA1c over the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a ≥ 5pts increase in KCCQ</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Proportion of patients with a ≥ 5pts increase in KCCQ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a ≥ 20% decrease in NTproBNP</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Proportion of patients with a ≥ 20% decrease in NTproBNP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a ≥ 5pts increase in KCCQ and a ≥ 20% decrease in NTproBNP</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Proportion of patients with a ≥ 5pts increase in KCCQ and a ≥ 20% decrease in NTproBNP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weight over 12 weeks</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Change in weight over 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systolic blood pressure over 12 weeks</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Change in systolic blood pressure over 12 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Chronic Heart Failure With Preserved Systolic Function</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dapagliflozin 10 mg oral tablet, once daily, for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dapagliflozin matching placebo oral tablet, once daily, for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 10Mg Oral Tablet</intervention_name>
    <description>Dapagliflozin 10Mg Oral Tablet</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <other_name>Farxiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin matching placebo</intervention_name>
    <description>Dapagliflozin matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo Oral Tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Documented type 2 diabetes for at least 3 months, or prediabetes. Those with type 2
             diabetes must be prescribed a lifestyle intervention alone or in combination with a
             stable dose(s) of at least one glucose-lowering medication during the 8 weeks prior to
             the screening visit.

          2. Hemoglobin A1c inclusion criteria as follows: i. Hemoglobin A1c of 6-11% (inclusive)
             for patients with documented type 2 diabetes receiving metformin monotherapy; ii.
             Hemoglobin A1c of 6.5-11% (inclusive) for patients with documented type 2 diabetes
             receiving any type of glucose-lowering medication (except metformin monotherapy); iii.
             Hemoglobin A1c of 6.0-6.9% (inclusive) for patients with documented type 2 diabetes
             receiving lifestyle intervention alone; iv. Hemoglobin A1c of &gt; 5.7% and &lt; 6.5 % for
             patients with pre-diabetes

          3. Symptoms of dyspnea (NYHA class II-IV) without evidence of a non-cardiac or ischemic
             explanation for dyspnea

          4. Ejection fraction (EF) ≥ 45% as determined on imaging study within 18 months of
             enrollment with no change in clinical status suggesting potential for deterioration in
             systolic function

          5. Elevated NT-proBNP ≥ 300 pg/ml or BNP ≥ 100 pg/ml. For patients with permanent atrial
             fibrillation inclusion thresholds will be BNP ≥ 125 pg/mL or NTproBNP ≥ 500 pg/mL

          6. Stable medical therapy for heart failure for 30 days

          7. On a diuretic ≥30 days prior to screening visit and a stable diuretic therapy for 14
             days

          8. At least one of the following: i. Hospitalization for decompensated HF in the last 12
             months; ii. Acute treatment for HF with intravenous loop diuretic or hemofiltration in
             the last 12 months; iii. Mean pulmonary capillary wedge pressure ≥15 mmHg or LV end
             diastolic pressure (LVEDP) ≥15 mmHg documented during catheterization at rest, or
             pulmonary capillary wedge pressure or LVEDP ≥25 mmHg documented during catheterization
             with exercise; iv. Structural heart disease evidenced by at least one of the following
             echo findings (any local measurement made within the 18 months prior to screening
             visit): 1) left atrial (LA) enlargement defined by at least one of the following: LA
             width ≥3.8cm or LA length ≥5.0 cm or LA area ≥20 cm2 or LA volume ≥55mL or LA volume
             index ≥29 mL/m2 2) OR left ventricular hypertrophy (LVH) defined by septal thickness
             or posterior wall thickness ≥1.1 cm.

        Exclusion Criteria:

          1. Decompensated heart failure (hospitalization for heart failure within the 30 days
             prior to screening)

          2. History of type 1 diabetes

          3. History of diabetic ketoacidosis

          4. Hemoglobin A1c &lt;5.7 or &gt;11% at the screening visit

          5. Estimated glomerular filtration rate (eGFR) &lt; 30 at the screening visit

          6. Admission for an acute coronary syndrome (ST-elevation MI, non-ST-elevation MI, or
             unstable angina), percutaneous coronary intervention, or cardiac surgery within 60
             days prior to the screening visit.

          7. Admission for cardiac resynchronization therapy (CRT) within 90 days prior to the
             screening visit

          8. Planned cardiovascular revascularization (percutaneous intervention or surgical) or
             major cardiac surgery (coronary artery bypass grafting, valve replacement, ventricular
             assist device, cardiac transplantation, or any other surgery requiring thoracotomy, or
             transcatheter aortic valve replacement) or CRT within the 90 days after the screening
             visit.

          9. Participation in any interventional clinical trial (with an investigational drug or
             device) that is not an observational registry within 30 days of the screening visit.

         10. History of hypersensitivity to dapagliflozin

         11. For women of child-bearing potential: Current or planned pregnancy or currently
             lactating.

         12. Life expectancy &lt;1 year at the screening visit

         13. Patients who are volume depleted based upon physical examination at the time of the
             screening or randomization visit

         14. BNP &lt;100 pg/mL and NTproBNP&lt;300 pg/mL at the screening visit. For patients with
             permanent atrial fibrillation exclusion thresholds will be BNP&lt;125 pg/mL and
             NTproBNP&lt;500pg/mL.

         15. Patients currently being treated with any SGLT-2 inhibitor (dapagliflozin,
             canagliflozin, empagliflozin) or having received treatment with any SGLT-2 inhibitor
             within the 12 weeks prior to the screening visit.

         16. Average supine systolic BP &lt;100 mmHg at the screening or randomization visit

         17. Past or current history of bladder cancer

         18. Active Hematuria

         19. Donation of blood or bone marrow 12 weeks prior to the screening visit and no planned
             donations during the study period

         20. Heart failure due to restrictive/infiltrative cardiomyopathy, active myocarditis,
             constrictive pericarditis, severe stenotic valve disease, and HOCM (hypertrophic
             obstructive cardiomyopathy).

         21. Heart failure due to severe aortic or mitral regurgitation

         22. Severe COPD thought to contribute to dyspnea

         23. Isolated right heart failure due to pulmonary disease

         24. Active and significant ischemia thought to contribute to dyspnea

         25. Documentation of previous EF &lt; 40% at any time

         26. Complex congenital heart disease

         27. Uncontrolled hypertension, defined as systolic blood pressure ≥200 mmHg during the
             screening visit

         28. Any other condition that in the judgment of the investigator would jeopardize the
             patient's participation in the study or that may interfere with the interpretation of
             study data or if the patient is considered unlikely to comply with study procedures,
             restrictions and requirements

         29. Bariatric surgery within the past 6 months or planned bariatric surgery within the
             study time course.

         30. CardioMems device implantation within previous 4 weeks or planned CardioMems
             implantation during study period

         31. For echo substudy only: history of poor echo windows as judged by the investigator

         32. For echo substudy only: patients with ventricular paced rhythm or left bundle branch
             block on the most recent clinically available 12-lead electrocardiogram.

         33. For echo substudy only: permanent atrial fibrillation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>119 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mikhail Kosiborod, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Saint Luke's Mid America Heart Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sheryl Windsor</last_name>
    <phone>8169329858</phone>
    <email>PRESERVED-HF@saint-lukes.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Heart Group of the Eastern Shore</name>
      <address>
        <city>Fairhope</city>
        <state>Alabama</state>
        <zip>36532</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>251-990-1920</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>323-442-7983</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Coast Cardiovascular Institute</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>904-493-3333</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charlotte Heart Group Research Center</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>941-613-0330</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>404-251-8959</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>312-695-3264</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chicago Medical Research</name>
      <address>
        <city>Hazel Crest</city>
        <state>Illinois</state>
        <zip>60429</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>708-798-8522</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>OSF HealthCare Cardiovascular Institute</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>309-589-1937</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-724-8241</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>734-232-6383</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>507-255-0876</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Mid America Heart Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>816-932-5989</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>314-454-7451</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>212-305-1368</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Francis Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11576</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>516-622-4528</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>336-716-6339</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>503-418-1679</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allegheny Health Network Research Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>412-359-6860</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>615-343-9071</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor Scott and White Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>214-865-3633</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>801-585-7295</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eastern Virginia Medical School</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>757-446-8485</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://druginfo.nlm.nih.gov/drugportal/name/dapagliflozin</url>
    <description>Dapagliflozin information</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2017</study_first_submitted>
  <study_first_submitted_qc>January 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2017</study_first_posted>
  <last_update_submitted>March 30, 2018</last_update_submitted>
  <last_update_submitted_qc>March 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>heart failure</keyword>
  <keyword>dapagliflozin</keyword>
  <keyword>SGLT-2 inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

